222 related articles for article (PubMed ID: 30575978)
1. Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study.
Tabuchi H; Katsurabara T; Mori M; Aoyama M; Obara T; Yasuda N; Kawano T; Imai T; Ieiri I; Kumagai Y
J Clin Pharmacol; 2019 May; 59(5):688-701. PubMed ID: 30575978
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis.
Tanaka Y; Takeuchi T; Umehara H; Nanki T; Yasuda N; Tago F; Kawakubo M; Kitahara Y; Hojo S; Kawano T; Imai T
Mod Rheumatol; 2018 Jan; 28(1):58-65. PubMed ID: 28681650
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease.
Matsuoka K; Naganuma M; Hibi T; Tsubouchi H; Oketani K; Katsurabara T; Hojo S; Takenaka O; Kawano T; Imai T; Kanai T
J Gastroenterol Hepatol; 2021 Aug; 36(8):2180-2186. PubMed ID: 33599356
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs.
Tanaka Y; Takeuchi T; Yamanaka H; Nanki T; Umehara H; Yasuda N; Tago F; Kitahara Y; Kawakubo M; Torii K; Hojo S; Kawano T; Imai T
Mod Rheumatol; 2021 Jul; 31(4):783-789. PubMed ID: 33427546
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Tanaka Y; Takeuchi T; Yamanaka H; Nanki T; Umehara H; Yasuda N; Tago F; Kitahara Y; Kawakubo M; Torii K; Hojo S; Kawano T; Imai T
Arthritis Rheumatol; 2021 Apr; 73(4):587-595. PubMed ID: 33038062
[TBL] [Abstract][Full Text] [Related]
6. Application of an electrochemiluminescence assay for quantification of E6011, an antifractalkine monoclonal antibody, to pharmacokinetic studies in monkeys and humans.
Aoyama M; Mano Y
J Clin Lab Anal; 2019 Jan; 33(1):e22625. PubMed ID: 30030862
[TBL] [Abstract][Full Text] [Related]
7. Long-term evaluation of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs.
Tanaka Y; Takeuchi T; Yamanaka H; Nanki T; Umehara H; Yasuda N; Tago F; Kitahara Y; Kawakubo M; Torii K; Hojo S; Kawano T; Imai T
Mod Rheumatol; 2023 Dec; 34(1):45-49. PubMed ID: 36680420
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate.
Tanaka Y; Takeuchi T; Yamanaka H; Nanki T; Umehara H; Yasuda N; Tago F; Kitahara Y; Kawakubo M; Torii K; Hojo S; Kawano T; Imai T
Mod Rheumatol; 2023 Dec; 34(1):37-44. PubMed ID: 36680426
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC
Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094
[TBL] [Abstract][Full Text] [Related]
10. Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers.
Rosario M; Wyant T; Leach T; Sankoh S; Scholz C; Parikh A; Fox I; Feagan BG
Clin Drug Investig; 2016 Nov; 36(11):913-923. PubMed ID: 27422740
[TBL] [Abstract][Full Text] [Related]
11. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
Jankovic J; Goodman I; Safirstein B; Marmon TK; Schenk DB; Koller M; Zago W; Ness DK; Griffith SG; Grundman M; Soto J; Ostrowitzki S; Boess FG; Martin-Facklam M; Quinn JF; Isaacson SH; Omidvar O; Ellenbogen A; Kinney GG
JAMA Neurol; 2018 Oct; 75(10):1206-1214. PubMed ID: 29913017
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti-TNF-like weak inducer of apoptosis (anti-TWEAK) monoclonal antibody.
Galluppi GR; Wisniacki N; Stebbins C
Br J Clin Pharmacol; 2016 Jul; 82(1):118-28. PubMed ID: 26896828
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
Xu Z; Bouman-Thio E; Comisar C; Frederick B; Van Hartingsveldt B; Marini JC; Davis HM; Zhou H
Br J Clin Pharmacol; 2011 Aug; 72(2):270-81. PubMed ID: 21392075
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers.
Lim JJ; Derby MA; Zhang Y; Deng R; Larouche R; Anderson M; Maia M; Carrier S; Pelletier I; Girard J; Kulkarni P; Newton E; Tavel JA
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559255
[TBL] [Abstract][Full Text] [Related]
15. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
Cardinal M; Kantaridis C; Zhu T; Sun P; Pittman DD; Murphy JE; Arkin S
J Thromb Haemost; 2018 Sep; 16(9):1722-1731. PubMed ID: 29908043
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.
Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y
Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447
[TBL] [Abstract][Full Text] [Related]
17. Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting
Magyarics Z; Leslie F; Bartko J; Rouha H; Luperchio S; Schörgenhofer C; Schwameis M; Derhaschnig U; Lagler H; Stiebellehner L; Firbas C; Weber S; Campanaro E; Jilma B; Nagy E; Stevens C
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138568
[TBL] [Abstract][Full Text] [Related]
18. Quantification of anti-drug antibodies against E6011, an anti-fractalkine monoclonal antibody, in monkey and human serum, by an electrochemiluminescence assay.
Aoyama M; Mano Y
J Pharmacol Toxicol Methods; 2023; 124():107470. PubMed ID: 37689367
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects.
Zhang X; Georgy A; Rowell L
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):443-55. PubMed ID: 23547848
[TBL] [Abstract][Full Text] [Related]
20. Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial.
Meininger V; Pradat PF; Corse A; Al-Sarraj S; Rix Brooks B; Caress JB; Cudkowicz M; Kolb SJ; Lange D; Leigh PN; Meyer T; Milleri S; Morrison KE; Orrell RW; Peters G; Rothstein JD; Shefner J; Lavrov A; Williams N; Overend P; Price J; Bates S; Bullman J; Krull D; Berges A; Abila B; Meno-Tetang G; Wurthner J
PLoS One; 2014; 9(5):e97803. PubMed ID: 24841795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
